PharmaMar initiates a Phase II trial with antitumor drug PM184 in advanced breast cancer

(Pharmamar) PharmaMar has announced the start of an open-label multi-center two-stage Phase II trial with the anti-tumor drug PM184. The trial will be conducted in 10 European clinical centers and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes.